alt

XIX International AIDS Conference (AIDS 2012)

July 2012, Washington, DC

AIDS 2012: Expanded Access to HIV Treatment Lowered AIDS Deaths Worldwide

Many low- and middle-income countries have begun to devote significant resources towards HIV/AIDS treatment, matching wealthy international donor countries, according to a new report release by the United Nations Joint Programme on AIDS (UNAIDS) in advance of the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. This increased funding has enabled an expansion of antiretroviral treatment that has helped reduced AIDS-related deaths by 100,000 over the past year.

Read more:

AIDS 2012: Isoniazid Preventive Therapy Reduces Risk of TB for HIV+ People on ART

Twelve months of isoniazid (INH) preventive therapy (IPT) significantly reduced the incidence of all tuberculosis (TB) diagnoses among HIV positive people who were taking concurrent antiretroviral therapy (ART) according to results of a large randomized study presented as a late-breaker at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.

alt

Read more:

AIDS 2012: Why Do Black Gay and Bisexual Men Have Higher HIV Rates? [VIDEO]

Several studies presented at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC, shed further light on disproportionately high rates of HIV prevalence and incidence among African-American men who have sex with men (MSM).alt

Read more:

AIDS 2012: Black Gay Men Have Higher HIV Rates Despite No Greater Risk Behavior

African-American gay and bisexual men in U.S. cities have a significantly higher likelihood of becoming infected with HIV despite the fact that they do not engage in more high-risk sex or drug use, according to studies presented at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC, and in an HIV-theme issue of The Lancet.

[Alan Guttirez from HIVandHepatitis.com interviews Gregorio Millett and Sheldon Fields about HIV disparities among black gay and bisexual men and how they might be overcome.]alt

Read more:

AIDS 2012: Raltegravir Remains Effective and Well-tolerated at 5 Years

The HIV integrase inhibitor raltegravir (Isentress) continued to demonstrate good efficacy as part of a first-line antiretroviral regimen and had a consistently favorable safety profile at 240 weeks in the STARTMRK trial, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.Another long-term analysis showed continued efficacy for treatment-experienced patients with extensive drug resistance.alt

Read more: